Literature DB >> 11104817

Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

K Ikuta1, S Suzuki, H Horikoshi, T Mukai, R B Luftig.   

Abstract

In this review we summarize multiple aspects of the human immunodeficiency virus (HIV) protease from both structural and functional viewpoints. After an introductory overview, we provide an up-to-date status report on protease inhibitors (PI). This proceeds from a discussion of PI structural design, to how PI are optimally utilized in highly active antiretroviral triple therapy (one PI along with two reverse transcriptase inhibitors), the emergence of PI resistance, and the natural role of secretory leukocyte PI. Then we switch to another focus: the interaction of HIV protease with other genes in acute and persistent infection, which in turn may have an effect on AIDS pathogenesis. We conclude with a discussion on future directions in HIV treatment, involving multiple-target anti-HIV therapy, vaccine development, and novel reactivation-inhibitory reagents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104817      PMCID: PMC99012          DOI: 10.1128/MMBR.64.4.725-745.2000

Source DB:  PubMed          Journal:  Microbiol Mol Biol Rev        ISSN: 1092-2172            Impact factor:   11.056


  364 in total

1.  Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes.

Authors:  A de Ronde; B Klaver; W Keulen; L Smit; J Goudsmit
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

2.  Differential susceptibility of resting CD4(+) T lymphocytes to a T-tropic and a macrophage (M)-tropic human immunodeficiency virus type 1 is associated with their surface expression of CD38 molecules.

Authors:  H Horikoshi; M Kinomoto; F Sasao; T Mukai; R B Luftig; K Ikuta
Journal:  Virus Res       Date:  2001-01       Impact factor: 3.303

3.  Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization.

Authors:  A Bouras; N Boggetto; Z Benatalah; E de Rosny; S Sicsic; M Reboud-Ravaux
Journal:  J Med Chem       Date:  1999-03-25       Impact factor: 7.446

4.  Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Authors:  D J Kempf; K C Marsh; G Kumar; A D Rodrigues; J F Denissen; E McDonald; M J Kukulka; A Hsu; G R Granneman; P A Baroldi; E Sun; D Pizzuti; J J Plattner; D W Norbeck; J M Leonard
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease.

Authors:  A A Bukovsky; T Dorfman; A Weimann; H G Göttlinger
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  Serial passage of human immunodeficiency virus type 1 generates misalignment deletions in non-essential accessory genes.

Authors:  T Nakaya; K Fujinaga; H Doi; S Suzuki; H Takahashi; Y Nishino; M Kishi; I Azuma; R B Luftig; K Ikuta
Journal:  Virus Res       Date:  1996-12       Impact factor: 3.303

7.  vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys.

Authors:  J Hoch; S M Lang; M Weeger; C Stahl-Hennig; C Coulibaly; U Dittmer; G Hunsmann; D Fuchs; J Müller; S Sopper
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors.

Authors:  D L Winslow; S Stack; R King; H Scarnati; A Bincsik; M J Otto
Journal:  AIDS Res Hum Retroviruses       Date:  1995-01       Impact factor: 2.205

9.  Biological characterization of nef in long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Huang; L Zhang; D D Ho
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  gp 120s derived from four syncytium-inducing HIV-1 strains induce different patterns of CD4 association with lymphocyte surface molecules.

Authors:  M J Feito; M Bragardo; D Buonfiglio; S Bonissoni; F Bottarel; F Malavasi; U Dianzani
Journal:  Int Immunol       Date:  1997-08       Impact factor: 4.823

View more
  3 in total

1.  The vpu protein of human immunodeficiency virus type 1 plays a protective role against virus-induced apoptosis in primary CD4(+) T lymphocytes.

Authors:  Satoshi Komoto; Shoutaro Tsuji; Madiha S Ibrahim; Yong-Gang Li; Jiranan Warachit; Koki Taniguchi; Kazuyoshi Ikuta
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?

Authors:  Tulio de Oliveira; Susan Engelbrecht; Estrelita Janse van Rensburg; Michelle Gordon; Karen Bishop; Jan zur Megede; Susan W Barnett; Sharon Cassol
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 3.  A novel HIV vaccine targeting the protease cleavage sites.

Authors:  Hongzhao Li; Robert W Omange; Francis A Plummer; Ma Luo
Journal:  AIDS Res Ther       Date:  2017-09-12       Impact factor: 2.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.